Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• "Moderate Buy" consensus from six analysts (five buy, one hold) with an average 1-year price target of $14.20.
• Recent broker actions include Truist boosting its price target to $17 with a buy rating, Barclays initiating coverage at overweight ($15), and Zacks upgrading to strong-buy.
• Shares trade around $13.25 (52‑week range $6.68–$15.42), the company has a $4.17B market cap and a PE of 57.6, and institutional investors own about 31.8% of the stock.

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $14.20.

A number of brokerages recently issued reports on AMRX. Weiss Ratings reiterated a "hold (c)" rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Truist Financial boosted their price target on shares of Amneal Pharmaceuticals from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Monday, March 2nd. Barclays started coverage on shares of Amneal Pharmaceuticals in a report on Monday, December 8th. They set an "overweight" rating and a $15.00 price objective for the company. Finally, Zacks Research upgraded shares of Amneal Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Friday.

Institutional Investors Weigh In On Amneal Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Spire Wealth Management boosted its stake in Amneal Pharmaceuticals by 66.6% in the fourth quarter. Spire Wealth Management now owns 2,558 shares of the company's stock worth $32,000 after purchasing an additional 1,023 shares in the last quarter. Intech Investment Management LLC increased its stake in shares of Amneal Pharmaceuticals by 1.2% in the fourth quarter. Intech Investment Management LLC now owns 97,573 shares of the company's stock valued at $1,229,000 after buying an additional 1,159 shares in the last quarter. Hsbc Holdings PLC increased its stake in shares of Amneal Pharmaceuticals by 1.6% in the fourth quarter. Hsbc Holdings PLC now owns 101,945 shares of the company's stock valued at $1,297,000 after buying an additional 1,569 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Amneal Pharmaceuticals by 2.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 68,137 shares of the company's stock valued at $859,000 after buying an additional 1,582 shares during the last quarter. Finally, Comerica Bank raised its holdings in shares of Amneal Pharmaceuticals by 56.1% in the fourth quarter. Comerica Bank now owns 4,690 shares of the company's stock valued at $59,000 after buying an additional 1,685 shares during the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Stock Performance

Shares of NASDAQ:AMRX opened at $13.25 on Tuesday. Amneal Pharmaceuticals has a 52 week low of $6.68 and a 52 week high of $15.42. The company's fifty day moving average is $13.80 and its 200-day moving average is $11.93. The company has a market capitalization of $4.17 billion, a PE ratio of 57.61 and a beta of 1.34.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.